---
title: CDMO Daily News — July 24, 2026
slug: daily-news-2026-07-24-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: July 24 CDMO daily: ImmuPharma Selects Thermo Fisher for Kapiglucagon Drug-Product CDMO Services; SK pharmteco Advances AAV Gene Therapy to Phase III with 20…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-07-24-cdmo
published_at: 2026-07-24T00:02:18.389Z
last_updated: 2026-07-24T00:03:12.899Z
---

### ImmuPharma Selects Thermo Fisher for Kapiglucagon Drug-Product CDMO Services
- ImmuPharma engaged [Thermo Fisher Scientific](/companies/thermofisher) as CDMO for Kapiglucagon, a glucagon prodrug targeting Type 1 diabetes.
- Thermo Fisher will support CMC activities, pharmaceutical development, and IND-enabling manufacturing for the program's advance toward clinical development.
- ImmuPharma plans accelerated development including a 505(b)(2) regulatory pathway, with funding secured for the next two years.

**Operational Impact**

Thermo Fisher's selection as DP CDMO for Kapiglucagon adds a Type 1 diabetes glucagon-prodrug program to its small-molecule development portfolio, supporting CMC and manufacturing through IND submission.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/immupharma-selects-thermo-fisher-as-cdmo-for-kapiglucagon-program)*

---

### [SK pharmteco](/companies/skpharmteco) Advances AAV Gene Therapy to Phase III with 20 Clinical Batches for Genethon DMD Program
- [SK pharmteco](/companies/skpharmteco)'s Yposkesi French facility has manufactured 20 AAV8 batches at 400 L scale, including 18 cGMP batches, supporting Genethon's GNT-0004 gene therapy from Phase I/II through Phase III authorization.
- Phase III trial for DMD launched in Europe and UK in 2025 following EMA and MHRA approvals; SK pharmteco continues manufacturing clinical supply and preparing commercial-scale documentation and process validation.
- Partnership demonstrates SK pharmteco's viral vector manufacturing capabilities and positions its French operations to support additional late-stage viral vector programs in Europe and beyond.

**Operational Impact**

[SK pharmteco](/companies/skpharmteco)'s demonstrated ability to scale AAV8 production to 400 L cGMP batches and navigate EMA/MHRA approvals for a pivotal Phase III trial reinforces its viral vector CDMO capacity in Europe and positions the French facility to absorb additional late-stage gene therapy programs.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/sk-pharmteco-supports-genethon-gene-therapy-program-through-phase-iii-manufacturing)*

---

### Restore Vision Selects [Forge Biologics](/companies/forgebiologics) for RV-001 AAV Gene Therapy Manufacturing
- [Forge Biologics](/companies/forgebiologics) will provide process development, cGMP manufacturing, analytical development, stability testing, and regulatory consultation for RV-001, an AAV gene therapy targeting retinitis pigmentosa.
- Manufacturing will occur at Forge's 200,000-square-foot Columbus, Ohio facility, with drug product shipped to Japan to support Phase 1/2 clinical trials.

**Operational Impact**

[Forge Biologics](/companies/forgebiologics)' Columbus facility is now committed to AAV process development and cGMP manufacturing for a Phase 1/2 gene therapy program with Japan-based clinical supply, demonstrating CDMO capacity allocation in the gene therapy segment.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/restore-vision-partners-with-forge-biologics-to-advance-rv-001-gene-therapy)*

## References

1. [PharmaSource RSS — ImmuPharma Selects Thermo Fisher for Kapiglucagon Drug-Product CDMO Services](https://pharmasource.global/content/news/cdmo-news/immupharma-selects-thermo-fisher-as-cdmo-for-kapiglucagon-program)
2. [PharmaSource RSS — SK pharmteco Advances AAV Gene Therapy to Phase III with 20 Clinical Batches for Genethon DMD Program](https://pharmasource.global/content/news/cdmo-news/sk-pharmteco-supports-genethon-gene-therapy-program-through-phase-iii-manufacturing)
3. [PharmaSource RSS — Restore Vision Selects Forge Biologics for RV-001 AAV Gene Therapy Manufacturing](https://pharmasource.global/content/news/cdmo-news/restore-vision-partners-with-forge-biologics-to-advance-rv-001-gene-therapy)

Source: https://www.cdmo.directory/posts/daily-news-2026-07-24-cdmo